<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>Chapter 10 ANCA vasculitis | LATINART</title>
  <meta name="description" content="A brief index of the landmark trials in nephrology &amp; renal transplant." />
  <meta name="generator" content="bookdown 0.22 and GitBook 2.6.7" />

  <meta property="og:title" content="Chapter 10 ANCA vasculitis | LATINART" />
  <meta property="og:type" content="book" />
  
  <meta property="og:image" content="/logo.png" />
  <meta property="og:description" content="A brief index of the landmark trials in nephrology &amp; renal transplant." />
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Chapter 10 ANCA vasculitis | LATINART" />
  
  <meta name="twitter:description" content="A brief index of the landmark trials in nephrology &amp; renal transplant." />
  <meta name="twitter:image" content="/logo.png" />

<meta name="author" content="Robert W Hunter" />


<meta name="date" content="2021-08-03" />

  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="glomerular-disease.html"/>
<link rel="next" href="lupus-nephritis.html"/>
<script src="libs/jquery-2.2.3/jquery.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />









<link href="libs/anchor-sections-1.0.1/anchor-sections.css" rel="stylesheet" />
<script src="libs/anchor-sections-1.0.1/anchor-sections.js"></script>




<link rel="stylesheet" href="style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="https://www.kidneyfish.net">KidneyFish</a></li>
<li><a href="./">LATINART</a></li>

<li class="divider"></li>
<li class="chapter" data-level="" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i>Preface</a></li>
<li class="chapter" data-level="1" data-path="intro.html"><a href="intro.html"><i class="fa fa-check"></i><b>1</b> Introduction</a></li>
<li class="part"><span><b>I AKI</b></span></li>
<li class="chapter" data-level="2" data-path="aki.html"><a href="aki.html"><i class="fa fa-check"></i><b>2</b> AKI</a><ul>
<li class="chapter" data-level="2.1" data-path="aki.html"><a href="aki.html#aki-trials-in-other-chapters"><i class="fa fa-check"></i><b>2.1</b> AKI trials in other chapters</a></li>
<li class="chapter" data-level="2.2" data-path="aki.html"><a href="aki.html#association-of-aki-with-mortality-morbidity"><i class="fa fa-check"></i><b>2.2</b> Association of AKI with mortality &amp; morbidity</a></li>
<li class="chapter" data-level="2.3" data-path="aki.html"><a href="aki.html#contrast-associated-nephropathy"><i class="fa fa-check"></i><b>2.3</b> Contrast-associated nephropathy</a></li>
<li class="chapter" data-level="2.4" data-path="aki.html"><a href="aki.html#hepatorenal-syndrome"><i class="fa fa-check"></i><b>2.4</b> Hepatorenal syndrome</a></li>
<li class="chapter" data-level="2.5" data-path="aki.html"><a href="aki.html#other-trials-in-aki"><i class="fa fa-check"></i><b>2.5</b> Other trials in AKI</a></li>
</ul></li>
<li class="part"><span><b>II CKD</b></span></li>
<li class="chapter" data-level="3" data-path="renal-anaemia.html"><a href="renal-anaemia.html"><i class="fa fa-check"></i><b>3</b> Renal anaemia</a><ul>
<li class="chapter" data-level="3.1" data-path="renal-anaemia.html"><a href="renal-anaemia.html#erythropoetin"><i class="fa fa-check"></i><b>3.1</b> Erythropoetin</a></li>
<li class="chapter" data-level="3.2" data-path="renal-anaemia.html"><a href="renal-anaemia.html#iron"><i class="fa fa-check"></i><b>3.2</b> Iron</a></li>
</ul></li>
<li class="chapter" data-level="4" data-path="ckd-mbd.html"><a href="ckd-mbd.html"><i class="fa fa-check"></i><b>4</b> CKD-MBD</a><ul>
<li class="chapter" data-level="4.1" data-path="ckd-mbd.html"><a href="ckd-mbd.html#cinacalcet"><i class="fa fa-check"></i><b>4.1</b> Cinacalcet</a></li>
<li class="chapter" data-level="4.2" data-path="ckd-mbd.html"><a href="ckd-mbd.html#phosphate-binders"><i class="fa fa-check"></i><b>4.2</b> Phosphate binders</a></li>
</ul></li>
<li class="part"><span><b>III Blood pressure &amp; proteinuria</b></span></li>
<li class="chapter" data-level="5" data-path="HTN-CVS.html"><a href="HTN-CVS.html"><i class="fa fa-check"></i><b>5</b> Hypertension &amp; cardiovascular risk</a><ul>
<li class="chapter" data-level="5.1" data-path="HTN-CVS.html"><a href="HTN-CVS.html#hypertension"><i class="fa fa-check"></i><b>5.1</b> Hypertension</a></li>
<li class="chapter" data-level="5.2" data-path="HTN-CVS.html"><a href="HTN-CVS.html#statins"><i class="fa fa-check"></i><b>5.2</b> Statins</a></li>
<li class="chapter" data-level="5.3" data-path="HTN-CVS.html"><a href="HTN-CVS.html#cardiovascular-risk"><i class="fa fa-check"></i><b>5.3</b> Cardiovascular risk</a></li>
<li class="chapter" data-level="5.4" data-path="HTN-CVS.html"><a href="HTN-CVS.html#renal-dennervation"><i class="fa fa-check"></i><b>5.4</b> Renal dennervation</a></li>
<li class="chapter" data-level="5.5" data-path="HTN-CVS.html"><a href="HTN-CVS.html#renovascular-disease"><i class="fa fa-check"></i><b>5.5</b> Renovascular disease</a></li>
</ul></li>
<li class="chapter" data-level="6" data-path="ckd-proteinuria.html"><a href="ckd-proteinuria.html"><i class="fa fa-check"></i><b>6</b> CKD &amp; proteinuria</a><ul>
<li class="chapter" data-level="6.1" data-path="ckd-proteinuria.html"><a href="ckd-proteinuria.html#egfr-calculation"><i class="fa fa-check"></i><b>6.1</b> eGFR calculation</a></li>
<li class="chapter" data-level="6.2" data-path="ckd-proteinuria.html"><a href="ckd-proteinuria.html#association-of-egfr-and-proteinuria-with-hard-outcomes"><i class="fa fa-check"></i><b>6.2</b> Association of eGFR and proteinuria with hard outcomes</a></li>
<li class="chapter" data-level="6.3" data-path="ckd-proteinuria.html"><a href="ckd-proteinuria.html#competing-risk-of-death"><i class="fa fa-check"></i><b>6.3</b> Competing risk of death</a></li>
<li class="chapter" data-level="6.4" data-path="ckd-proteinuria.html"><a href="ckd-proteinuria.html#rasi-progression-in-non-diabetic-disease"><i class="fa fa-check"></i><b>6.4</b> RASi &amp; progression in non-diabetic disease</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="diabetic-kidney-disease.html"><a href="diabetic-kidney-disease.html"><i class="fa fa-check"></i><b>7</b> Diabetic kidney disease</a><ul>
<li class="chapter" data-level="7.1" data-path="diabetic-kidney-disease.html"><a href="diabetic-kidney-disease.html#glycaemic-control"><i class="fa fa-check"></i><b>7.1</b> Glycaemic control</a></li>
<li class="chapter" data-level="7.2" data-path="diabetic-kidney-disease.html"><a href="diabetic-kidney-disease.html#DKD_RASi"><i class="fa fa-check"></i><b>7.2</b> RAS blockade</a></li>
<li class="chapter" data-level="7.3" data-path="diabetic-kidney-disease.html"><a href="diabetic-kidney-disease.html#drasi_DKD"><i class="fa fa-check"></i><b>7.3</b> Dual RAAS blockade</a></li>
<li class="chapter" data-level="7.4" data-path="diabetic-kidney-disease.html"><a href="diabetic-kidney-disease.html#sglti"><i class="fa fa-check"></i><b>7.4</b> SGLTi</a></li>
</ul></li>
<li class="part"><span><b>IV BODY FLUIDS</b></span></li>
<li class="chapter" data-level="8" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html"><i class="fa fa-check"></i><b>8</b> Fluids, electrolytes &amp; acid-base</a><ul>
<li class="chapter" data-level="8.1" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#hyponatraemia"><i class="fa fa-check"></i><b>8.1</b> Hyponatraemia</a></li>
<li class="chapter" data-level="8.2" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#hyperkalaemia"><i class="fa fa-check"></i><b>8.2</b> Hyperkalaemia</a></li>
<li class="chapter" data-level="8.3" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#fluids"><i class="fa fa-check"></i><b>8.3</b> IV fluid therapy</a></li>
<li class="chapter" data-level="8.4" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#diuretic-therapy"><i class="fa fa-check"></i><b>8.4</b> Diuretic therapy</a></li>
<li class="chapter" data-level="8.5" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#metabolic-acidosis"><i class="fa fa-check"></i><b>8.5</b> Metabolic acidosis</a><ul>
<li class="chapter" data-level="8.5.1" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#acidosis-of-ckd"><i class="fa fa-check"></i><b>8.5.1</b> Acidosis of CKD</a></li>
<li class="chapter" data-level="8.5.2" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#renal-tubular-acidosis"><i class="fa fa-check"></i><b>8.5.2</b> Renal tubular acidosis</a></li>
<li class="chapter" data-level="8.5.3" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#severe-metabolic-acidosis"><i class="fa fa-check"></i><b>8.5.3</b> Severe metabolic acidosis</a></li>
</ul></li>
</ul></li>
<li class="part"><span><b>V SPECIFIC KIDNEY DISEASES</b></span></li>
<li class="chapter" data-level="9" data-path="glomerular-disease.html"><a href="glomerular-disease.html"><i class="fa fa-check"></i><b>9</b> Glomerular disease</a><ul>
<li class="chapter" data-level="9.1" data-path="glomerular-disease.html"><a href="glomerular-disease.html#proteinuria"><i class="fa fa-check"></i><b>9.1</b> Proteinuria</a></li>
<li class="chapter" data-level="9.2" data-path="glomerular-disease.html"><a href="glomerular-disease.html#igan"><i class="fa fa-check"></i><b>9.2</b> IgAN</a></li>
<li class="chapter" data-level="9.3" data-path="glomerular-disease.html"><a href="glomerular-disease.html#membranous"><i class="fa fa-check"></i><b>9.3</b> Membranous</a></li>
<li class="chapter" data-level="9.4" data-path="glomerular-disease.html"><a href="glomerular-disease.html#minimal-change"><i class="fa fa-check"></i><b>9.4</b> Minimal change</a></li>
<li class="chapter" data-level="9.5" data-path="glomerular-disease.html"><a href="glomerular-disease.html#fsgs"><i class="fa fa-check"></i><b>9.5</b> FSGS</a></li>
<li class="chapter" data-level="9.6" data-path="glomerular-disease.html"><a href="glomerular-disease.html#Apol1"><i class="fa fa-check"></i><b>9.6</b> APOL1 nephropathy</a></li>
<li class="chapter" data-level="9.7" data-path="glomerular-disease.html"><a href="glomerular-disease.html#ahus"><i class="fa fa-check"></i><b>9.7</b> aHUS</a></li>
</ul></li>
<li class="chapter" data-level="10" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html"><i class="fa fa-check"></i><b>10</b> ANCA vasculitis</a><ul>
<li class="chapter" data-level="10.1" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#induction"><i class="fa fa-check"></i><b>10.1</b> Induction</a><ul>
<li class="chapter" data-level="10.1.1" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#glucocorticoids-plasma-exchange"><i class="fa fa-check"></i><b>10.1.1</b> Glucocorticoids &amp; Plasma-exchange</a></li>
<li class="chapter" data-level="10.1.2" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#cyclophosphamide"><i class="fa fa-check"></i><b>10.1.2</b> Cyclophosphamide</a></li>
<li class="chapter" data-level="10.1.3" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#rituximab"><i class="fa fa-check"></i><b>10.1.3</b> Rituximab</a></li>
<li class="chapter" data-level="10.1.4" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#other-agents"><i class="fa fa-check"></i><b>10.1.4</b> Other agents</a></li>
</ul></li>
<li class="chapter" data-level="10.2" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#maintenance"><i class="fa fa-check"></i><b>10.2</b> Maintenance</a></li>
<li class="chapter" data-level="10.3" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#adjunctive-therapies"><i class="fa fa-check"></i><b>10.3</b> Adjunctive therapies</a></li>
</ul></li>
<li class="chapter" data-level="11" data-path="lupus-nephritis.html"><a href="lupus-nephritis.html"><i class="fa fa-check"></i><b>11</b> Lupus nephritis</a><ul>
<li class="chapter" data-level="11.1" data-path="lupus-nephritis.html"><a href="lupus-nephritis.html#induction-1"><i class="fa fa-check"></i><b>11.1</b> Induction</a></li>
<li class="chapter" data-level="11.2" data-path="lupus-nephritis.html"><a href="lupus-nephritis.html#maintenance-1"><i class="fa fa-check"></i><b>11.2</b> Maintenance</a></li>
<li class="chapter" data-level="11.3" data-path="lupus-nephritis.html"><a href="lupus-nephritis.html#newer-therapies"><i class="fa fa-check"></i><b>11.3</b> Newer therapies</a></li>
</ul></li>
<li class="chapter" data-level="12" data-path="adpkd.html"><a href="adpkd.html"><i class="fa fa-check"></i><b>12</b> ADPKD</a><ul>
<li class="chapter" data-level="12.1" data-path="adpkd.html"><a href="adpkd.html#blood-pressure-targets-and-rasi"><i class="fa fa-check"></i><b>12.1</b> Blood pressure targets and RASi</a></li>
<li class="chapter" data-level="12.2" data-path="adpkd.html"><a href="adpkd.html#vasopressin-antagonist-therapy"><i class="fa fa-check"></i><b>12.2</b> Vasopressin antagonist therapy</a></li>
</ul></li>
<li class="chapter" data-level="13" data-path="miscellaneous-conditions.html"><a href="miscellaneous-conditions.html"><i class="fa fa-check"></i><b>13</b> Miscellaneous conditions</a><ul>
<li class="chapter" data-level="13.1" data-path="miscellaneous-conditions.html"><a href="miscellaneous-conditions.html#myeloma"><i class="fa fa-check"></i><b>13.1</b> Myeloma</a></li>
<li class="chapter" data-level="13.2" data-path="miscellaneous-conditions.html"><a href="miscellaneous-conditions.html#pregnancy"><i class="fa fa-check"></i><b>13.2</b> Pregnancy</a></li>
<li class="chapter" data-level="13.3" data-path="miscellaneous-conditions.html"><a href="miscellaneous-conditions.html#ain"><i class="fa fa-check"></i><b>13.3</b> AIN</a></li>
<li class="chapter" data-level="13.4" data-path="miscellaneous-conditions.html"><a href="miscellaneous-conditions.html#tuberous-sclerosis"><i class="fa fa-check"></i><b>13.4</b> Tuberous sclerosis</a></li>
<li class="chapter" data-level="13.5" data-path="miscellaneous-conditions.html"><a href="miscellaneous-conditions.html#other"><i class="fa fa-check"></i><b>13.5</b> Other</a></li>
</ul></li>
<li class="part"><span><b>VI RRT &amp; TRANSPLANT</b></span></li>
<li class="chapter" data-level="14" data-path="acute-RRT.html"><a href="acute-RRT.html"><i class="fa fa-check"></i><b>14</b> Acute dialysis</a><ul>
<li class="chapter" data-level="14.1" data-path="acute-RRT.html"><a href="acute-RRT.html#dose"><i class="fa fa-check"></i><b>14.1</b> Dose</a></li>
<li class="chapter" data-level="14.2" data-path="acute-RRT.html"><a href="acute-RRT.html#timing"><i class="fa fa-check"></i><b>14.2</b> Timing</a></li>
</ul></li>
<li class="chapter" data-level="15" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html"><i class="fa fa-check"></i><b>15</b> Chronic dialysis</a><ul>
<li class="chapter" data-level="15.1" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html#chronic-haemodialysis"><i class="fa fa-check"></i><b>15.1</b> Chronic Haemodialysis</a><ul>
<li class="chapter" data-level="15.1.1" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html#modality"><i class="fa fa-check"></i><b>15.1.1</b> Modality</a></li>
<li class="chapter" data-level="15.1.2" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html#dose-1"><i class="fa fa-check"></i><b>15.1.2</b> Dose</a></li>
<li class="chapter" data-level="15.1.3" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html#initiation"><i class="fa fa-check"></i><b>15.1.3</b> Initiation</a></li>
</ul></li>
<li class="chapter" data-level="15.2" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html#peritoneal-dialysis"><i class="fa fa-check"></i><b>15.2</b> Peritoneal Dialysis</a></li>
</ul></li>
<li class="chapter" data-level="16" data-path="transplant.html"><a href="transplant.html"><i class="fa fa-check"></i><b>16</b> Transplant</a><ul>
<li class="chapter" data-level="16.1" data-path="transplant.html"><a href="transplant.html#donors"><i class="fa fa-check"></i><b>16.1</b> Donors</a><ul>
<li class="chapter" data-level="16.1.1" data-path="transplant.html"><a href="transplant.html#donor-types"><i class="fa fa-check"></i><b>16.1.1</b> Donor types</a></li>
<li class="chapter" data-level="16.1.2" data-path="transplant.html"><a href="transplant.html#donor-aki"><i class="fa fa-check"></i><b>16.1.2</b> Donor AKI</a></li>
<li class="chapter" data-level="16.1.3" data-path="transplant.html"><a href="transplant.html#ischaemic-time"><i class="fa fa-check"></i><b>16.1.3</b> Ischaemic time</a></li>
</ul></li>
<li class="chapter" data-level="16.2" data-path="transplant.html"><a href="transplant.html#immunosuppression"><i class="fa fa-check"></i><b>16.2</b> Immunosuppression</a></li>
<li class="chapter" data-level="16.3" data-path="transplant.html"><a href="transplant.html#desensitisation"><i class="fa fa-check"></i><b>16.3</b> Desensitisation</a></li>
<li class="chapter" data-level="16.4" data-path="transplant.html"><a href="transplant.html#cmv-disease"><i class="fa fa-check"></i><b>16.4</b> CMV disease</a></li>
<li class="chapter" data-level="16.5" data-path="transplant.html"><a href="transplant.html#statin_Tx"><i class="fa fa-check"></i><b>16.5</b> CVS risk</a></li>
<li class="chapter" data-level="16.6" data-path="transplant.html"><a href="transplant.html#rejection"><i class="fa fa-check"></i><b>16.6</b> Rejection</a></li>
</ul></li>
<li class="part"><span><b>VII OTHER</b></span></li>
<li class="chapter" data-level="17" data-path="historic-trials.html"><a href="historic-trials.html"><i class="fa fa-check"></i><b>17</b> Historic trials</a></li>
<li class="chapter" data-level="18" data-path="seminal-basic-science.html"><a href="seminal-basic-science.html"><i class="fa fa-check"></i><b>18</b> Seminal basic science</a></li>
<li class="chapter" data-level="19" data-path="other-non-renal-specialties.html"><a href="other-non-renal-specialties.html"><i class="fa fa-check"></i><b>19</b> Other (non-renal) specialties</a><ul>
<li class="chapter" data-level="19.1" data-path="other-non-renal-specialties.html"><a href="other-non-renal-specialties.html#critical-care"><i class="fa fa-check"></i><b>19.1</b> Critical care</a><ul>
<li class="chapter" data-level="19.1.1" data-path="other-non-renal-specialties.html"><a href="other-non-renal-specialties.html#sepsis"><i class="fa fa-check"></i><b>19.1.1</b> Sepsis</a></li>
</ul></li>
<li class="chapter" data-level="19.2" data-path="other-non-renal-specialties.html"><a href="other-non-renal-specialties.html#cardio"><i class="fa fa-check"></i><b>19.2</b> Cardiology</a></li>
<li class="chapter" data-level="19.3" data-path="other-non-renal-specialties.html"><a href="other-non-renal-specialties.html#haematology"><i class="fa fa-check"></i><b>19.3</b> Haematology</a></li>
</ul></li>
<li class="divider"></li>
<li><a href="https://github.com/rstudio/bookdown" target="blank">Published with bookdown</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">LATINART</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="anca-vasculitis" class="section level1">
<h1><span class="header-section-number">Chapter 10</span> ANCA vasculitis</h1>
<div id="induction" class="section level2">
<h2><span class="header-section-number">10.1</span> Induction</h2>
<div id="glucocorticoids-plasma-exchange" class="section level3">
<h3><span class="header-section-number">10.1.1</span> Glucocorticoids &amp; Plasma-exchange</h3>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/17582159"><strong>MEPEX</strong></a> (2007): <img src="Logo_RCT.png" style="height:1.2em" /> - 3g IV methylprednisolone <em>vs.</em> PLEX (in addition to CYC and pred) in patients with AAV and Cr &gt; 500 mcM. The PLEX group fared better for primary compositive outcome of dialysis-independent survival at 3 months. 1-year survival did not differ between groups. <a href="https://www.ncbi.nlm.nih.gov/pubmed/23615499">Longer-term follow-up</a> found no difference between groups with respect to composite of mortality and ESRF.</p>

<div class="box_landmark">
<p><strong>PEXIVAS</strong> (not yet published but reported at ERA-EDTA 2018): <img src="Logo_RCT.png" style="height:1.2em" /> <img src="Logo_SEM.png" style="height:1.2em" /> - factorial, low- <em>vs.</em> standard-dose glucocorticoids and plasma-exchange <em>vs.</em> no plasma exchange. Median Cr 330; alveolar haemorrhage in 25%. Primary outcome was composite of death and ESRF at 2 yrs. Lower-dose steroids were non-inferior w.r.t. primary outcome are caused fewer serious infections during first year. PLEX had no effect on primary outcome (overall and in pre-specified subgroups including Cr &gt; 500 and lung haemorrhage).</p>
</div>

</div>
<div id="cyclophosphamide" class="section level3">
<h3><span class="header-section-number">10.1.2</span> Cyclophosphamide</h3>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/16052573"><strong>NORAM</strong></a> (2005): <img src="Logo_RCT.png" style="height:1.2em" /> - cyclophosphamide <em>vs.</em> methotrexate for early, mild disease. MTX was non-inferior to CYC at inducing remission by 6 months but lead to higher rates of disease relapse.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/19451574"><strong>CYCLOPS</strong></a> (2009) (with longer-term <a href="https://www.ncbi.nlm.nih.gov/pubmed/22128076">follow-up data</a> published in 2012): <img src="Logo_RCT.png" style="height:1.2em" /> - pulsed IV <em>vs.</em> daily oral cyclophosphamide. IV CYC was as effective as daily oral CYC at inducing remission but was associated with higher rates of disease relapse. Leukopaenia was more common with daily oral CYC. Long-term survival and renal function did not differ between groups.</p>
</div>
<div id="rituximab" class="section level3">
<h3><span class="header-section-number">10.1.3</span> Rituximab</h3>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/20647198"><strong>RITUXIVAS</strong></a> (2010): <img src="Logo_RCT.png" style="height:1.2em" /> - rituximab (plus two pulses of IV CYC) <em>vs.</em> CYC in newly-diagnosed AAV. Outcomes at 12 months did not differ between groups.</p>

<div class="box_landmark">
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/20647199"><strong>RAVE</strong></a> (2010): <img src="Logo_RCT.png" style="height:1.2em" /> <img src="Logo_SEM.png" style="height:1.2em" /> - rituximab <em>vs.</em> cyclophosphamide. RTX was non-inferior to CYC at inducing remission in patients with AAV (first presentation and in relapsing disease).</p>
</div>

</div>
<div id="other-agents" class="section level3">
<h3><span class="header-section-number">10.1.4</span> Other agents</h3>
<p><strong>MMF</strong> can be used for induction in less severe disease.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/17179175"><strong>Stassen et al.</strong></a> (2007): <img src="Logo_OBS.png" style="height:1.2em" /> - MMF in patients in whom CYC was contraindicated.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/30612116"><strong>MYCYC</strong></a> (2019): <img src="Logo_RCT.png" style="height:1.2em" /> - MMF <em>vs.</em> IV cyclophosphamide for induction of remission in ANCA vasculitis. MMF was non-inferior at inducing remission by 6 months. Relapse rate was higher in MMF group.</p>
</div>
</div>
<div id="maintenance" class="section level2">
<h2><span class="header-section-number">10.2</span> Maintenance</h2>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/12840090"><strong>CYCAZAREM</strong></a> (2003): <img src="Logo_RCT.png" style="height:1.2em" /> - azathioprine <em>vs.</em> cyclophosphamide after CYC induction for the maintenance of remission in AAV. Relapse rates did not differ between two groups.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/21060104"><strong>IMPROVE</strong></a> (2010): <img src="Logo_RCT.png" style="height:1.2em" /> - MMF <em>vs.</em> aza for maintenance after CYC induction. MMF was less effective at preventing disease relapse.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/27242368"><strong>Sanders et al.</strong></a> (2015): <img src="Logo_RCT.png" style="height:1.2em" /> - standard (c. 2 yrs) <em>vs.</em> extended (c. 4 yrs) aza after CYC induction. No difference between groups in disease-free survival at 4 yrs.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/25372085"><strong>MAINRITSAN 1</strong></a> (2014): <img src="Logo_RCT.png" style="height:1.2em" /> - rituximab (500 mg 6-monthly) <em>vs.</em> azathioprine after CYC induction for the maintenance of remission. RTX was better at preventing relapse; adverse events did not differ between groups.</p>
<p>[<strong>RITAZAREM</strong>] (not yet published): RTX <em>vs.</em> aza after RTX induction for relapsing disease.</p>
</div>
<div id="adjunctive-therapies" class="section level2">
<h2><span class="header-section-number">10.3</span> Adjunctive therapies</h2>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/8637536"><strong>Stegeman et al.</strong></a> (1996): <img src="Logo_RCT.png" style="height:1.2em" /> - co-trimoxazole <em>vs.</em> placebo in GPA. Co-trimoxaozle reduced risk of relapse and also rates of infection. 20% of patients in septrin group discontinued therapy for side-effects.</p>

</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="glomerular-disease.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="lupus-nephritis.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/lunr.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": null,
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 1
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": null,
"toc": {
"collapse": "section"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "true";
    if (src === "" || src === "true") src = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:")
      if (/^https?:/.test(src))
        src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
